Protara Other Assets vs Property Plant And Equipment Net Analysis
TARA Stock | USD 2.94 0.34 13.08% |
Protara Therapeutics financial indicator trend analysis is much more than just breaking down Protara Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Protara Therapeutics is a good investment. Please check the relationship between Protara Therapeutics Other Assets and its Property Plant And Equipment Net accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.
Other Assets vs Property Plant And Equipment Net
Other Assets vs Property Plant And Equipment Net Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Protara Therapeutics Other Assets account and Property Plant And Equipment Net. At this time, the significance of the direction appears to have very week relationship.
The correlation between Protara Therapeutics' Other Assets and Property Plant And Equipment Net is 0.24. Overlapping area represents the amount of variation of Other Assets that can explain the historical movement of Property Plant And Equipment Net in the same time period over historical financial statements of Protara Therapeutics, assuming nothing else is changed. The correlation between historical values of Protara Therapeutics' Other Assets and Property Plant And Equipment Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Assets of Protara Therapeutics are associated (or correlated) with its Property Plant And Equipment Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant And Equipment Net has no effect on the direction of Other Assets i.e., Protara Therapeutics' Other Assets and Property Plant And Equipment Net go up and down completely randomly.
Correlation Coefficient | 0.24 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Other Assets
Property Plant And Equipment Net
The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.Most indicators from Protara Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Protara Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.At present, Protara Therapeutics' Enterprise Value Over EBITDA is projected to decrease significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.31, whereas Selling General Administrative is forecasted to decline to about 15.3 M.
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 117K | 248K | 309K | 231.7K | Interest Income | 2.0M | 2.2M | 3.0M | 3.1M |
Protara Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Protara Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Protara Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 7.0M | 203.2M | 172.6M | 113.3M | 79.0M | 92.2M | |
Other Current Liab | 320K | 1.7M | 1.6M | 2.3M | 1.7M | 2.3M | |
Total Current Liabilities | 583K | 2.9M | 4.3M | 5.7M | 6.1M | 4.8M | |
Total Stockholder Equity | 6.4M | 199.2M | 161.9M | 102.1M | 68.3M | 85.5M | |
Net Tangible Assets | (12.1M) | 169.7M | 132.4M | 102.1M | 117.4M | 71.9M | |
Property Plant And Equipment Net | 459K | 1.2M | 8.9M | 7.9M | 6.6M | 6.9M | |
Net Debt | (6.2M) | (167.5M) | (28.5M) | (17.7M) | (34.1M) | (35.8M) | |
Retained Earnings | (225.5M) | (46.8M) | (94.0M) | (160.0M) | (200.4M) | (210.4M) | |
Accounts Payable | 263K | 914K | 954K | 1.6M | 2.4M | 2.6M | |
Cash | 6.2M | 168.6M | 35.7M | 24.1M | 39.6M | 50.6M | |
Non Current Assets Total | 581K | 33.7M | 79.5M | 27.1M | 10.2M | 16.9M | |
Non Currrent Assets Other | 122K | 3.0M | 1.6M | 1.4M | 3.7M | 3.9M | |
Cash And Short Term Investments | 6.2M | 168.6M | 91.2M | 84.4M | 65.6M | 73.7M | |
Retained Earnings Total Equity | (189.7M) | (210.5M) | (225.5M) | (46.8M) | (42.1M) | (44.2M) | |
Common Stock Shares Outstanding | 64.4K | 7.2M | 11.2M | 11.3M | 11.3M | 11.9M | |
Liabilities And Stockholders Equity | 7.0M | 203.2M | 172.6M | 113.3M | 79.0M | 92.2M | |
Capital Surpluse | 203.0M | 209.4M | 213.4M | 246.0M | 282.9M | 228.9M | |
Other Current Assets | 744K | 837K | 1.9M | 1.3M | 2.9M | 1.6M | |
Other Stockholder Equity | 213.4M | 246.0M | 256.1M | 262.7M | 268.7M | 237.6M | |
Total Liab | 583K | 3.9M | 10.7M | 11.2M | 10.6M | 6.7M | |
Property Plant And Equipment Gross | 0.0 | 1.2M | 8.9M | 7.9M | 7.4M | 7.8M | |
Total Current Assets | 7.0M | 169.4M | 93.1M | 86.1M | 68.7M | 75.4M | |
Accumulated Other Comprehensive Income | 3K | 0.0 | (211K) | (688K) | (31K) | (32.6K) | |
Common Stock | 18K | 19K | 3K | 11K | 9.9K | 10.6K | |
Property Plant Equipment | 459K | 1.2M | 8.9M | 7.9M | 9.0M | 9.5M | |
Other Assets | (581K) | 1.9M | 1.6M | 1.4M | 1.0 | 0.95 | |
Non Current Liabilities Total | 263K | 999K | 6.4M | 5.5M | 4.5M | 3.2M | |
Net Invested Capital | (12.1M) | 199.2M | 161.9M | 102.1M | 68.3M | 95.0M | |
Net Working Capital | 6.4M | 166.5M | 88.8M | 80.4M | 62.6M | 77.9M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Protara Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protara Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protara Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protara Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Return On Assets (0.28) | Return On Equity (0.46) |
The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.